Research Paper Volume 11, Issue 11 pp 3574—3584

Figure 3. TGF-β1 induces cellular senescence in VSMCs. (A) TGF-β1 concentrations in serum from control donors and MFS patients was measured using an ELISA. n=6. (B) Western blotting and quantitative analysis of TGF-β1 levels in control- and MFS-VSMCs. n=3. (C) Western blotting and quantitative analysis of TGF-β1, p53 and p21 levels in control-VSMCs left untreated or treated with TGF-β1 or TGF-β1 combined with control-siRNA or TGF-β1-siRNA. n=3. (D) Representative images and quantitative analysis of SA-β-gal staining in control-VSMCs left untreated or treated with TGF-β1 or TGF-β1 combined with control-siRNA or TGF-β1-siRNA. n=3. Numbers of SA-β-gal-positive cells are expressed as percentages of the total cells. Data are expressed as the mean±SEM. *p<0.05, ***p<0.01, ***p<0.001.